Clinical Trials

The Forbes Norris ALS Research Center has started a new research trial and asks for ALS patients to submit a blood sample for genetic testing.

The study will collect 250 blood samples from ALS patients in a three month time period.

If you are willing to participate please read this article for contact information.

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified February 2017

Phase II clinical trial of a molecule drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis.

Scientists at Mount Sinai School of Medicine have identified the first biomarkers for amyotrophic lateral sclerosis (ALS). These findings pave the way for a reliable test that will identify ALS sufferers at an earlier stage of the disease, and give more chances to companies developing disease-modifying drugs.

Conditions:   Kidney Transplant;   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Cyclosporin;   Drug: Tacrolimus;   Behavioral: 'Diabetes Education / Management'
Sponsor:   Stanford University
Completed - verified November 2016

Conditions:   Multiple Sclerosis (MS);   Relapsing-Remitting Multiple Sclerosis
Interventions:   Drug: Granulocyte-colony stimulating factor (G-CSF) and prednisone;   Drug: Carmustine, etoposide, cytarabine, and melphalan (BEAM);   Procedure: Autologous hematopoietic stem cell transplant
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
Completed - verified November 2016

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Biological: alemtuzumab;   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: rituximab;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsor:   German CLL Study Group
Completed - verified April 2007

Condition:   Vasculitis
Interventions:   Biological: Autologous Stem Cell Transplant;   Biological: Allogeneic Stem Cell Transplant
Sponsor:   Northwestern University
Terminated - verified July 2016

Conditions:   Immunosuppresion;   Thrombocytopenia;   Pancytopenia;   Neutropenia
Interventions:   Biological: Anti-thymocyte globulin (rabbit);   Biological: Anti-thymocyte globulin (horse);   Drug: Cyclosporine
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 15, 2016

The primary aim of the drug trial is to determine whether treatment with thalidomide is safe and well tolerated in conjunction with riluzole and whether patients with ALS can tolerate daily doses of up to 400 mg.